Cantargia AB (publ) (CANTA.ST)
SEK 1.83
(1.05%)
SEK 1.83
(1.05%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 54.97 Million SEK | -35.42% |
| 2022 | 85.11 Million SEK | 26.1% |
| 2021 | 67.49 Million SEK | 101.02% |
| 2020 | 33.57 Million SEK | 41.18% |
| 2019 | 23.78 Million SEK | 45.04% |
| 2018 | 16.39 Million SEK | -42.12% |
| 2017 | 28.33 Million SEK | 172.85% |
| 2016 | 10.38 Million SEK | 212.02% |
| 2015 | 3.32 Million SEK | -79.24% |
| 2014 | 16.03 Million SEK | 1768.34% |
| 2013 | 858.07 Thousand SEK | 23.05% |
| 2012 | 697.32 Thousand SEK | -19.04% |
| 2011 | 861.27 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 38.4 Million SEK | -30.13% |
| 2024 Q2 | 31.35 Million SEK | -18.35% |
| 2023 FY | 54.97 Million SEK | -35.42% |
| 2023 Q2 | 81.74 Million SEK | -12.61% |
| 2023 Q3 | 54.72 Million SEK | -33.05% |
| 2023 Q4 | 54.97 Million SEK | 0.44% |
| 2023 Q1 | 93.53 Million SEK | 9.89% |
| 2022 Q4 | 85.11 Million SEK | 33.31% |
| 2022 Q1 | 92.34 Million SEK | 36.8% |
| 2022 Q2 | 69.05 Million SEK | -25.22% |
| 2022 FY | 85.11 Million SEK | 26.1% |
| 2022 Q3 | 63.84 Million SEK | -7.54% |
| 2021 Q2 | 69.19 Million SEK | 26.25% |
| 2021 Q3 | 62.87 Million SEK | -9.14% |
| 2021 Q4 | 67.49 Million SEK | 7.36% |
| 2021 Q1 | 54.8 Million SEK | 63.22% |
| 2021 FY | 67.49 Million SEK | 101.02% |
| 2020 FY | 33.57 Million SEK | 41.18% |
| 2020 Q3 | 29.49 Million SEK | -9.38% |
| 2020 Q2 | 32.54 Million SEK | 30.1% |
| 2020 Q4 | 33.57 Million SEK | 13.87% |
| 2020 Q1 | 25.01 Million SEK | 5.18% |
| 2019 Q2 | 19.94 Million SEK | -25.3% |
| 2019 Q1 | 26.7 Million SEK | 62.84% |
| 2019 FY | 23.78 Million SEK | 45.04% |
| 2019 Q4 | 23.78 Million SEK | -32.57% |
| 2019 Q3 | 35.27 Million SEK | 76.84% |
| 2018 Q4 | 16.39 Million SEK | 26.41% |
| 2018 Q3 | 12.97 Million SEK | -11.65% |
| 2018 FY | 16.39 Million SEK | -42.12% |
| 2018 Q1 | 19.05 Million SEK | -32.75% |
| 2018 Q2 | 14.68 Million SEK | -22.95% |
| 2017 Q4 | 28.33 Million SEK | 311.52% |
| 2017 FY | 28.33 Million SEK | 172.85% |
| 2017 Q1 | 10.46 Million SEK | 0.73% |
| 2017 Q2 | 8.98 Million SEK | -14.08% |
| 2017 Q3 | 6.88 Million SEK | -23.39% |
| 2016 Q3 | 9.44 Million SEK | 48.59% |
| 2016 FY | 10.38 Million SEK | 212.02% |
| 2016 Q4 | 10.38 Million SEK | 9.9% |
| 2016 Q2 | 6.35 Million SEK | 11.64% |
| 2016 Q1 | 5.69 Million SEK | 71.15% |
| 2015 Q2 | 3.89 Million SEK | 34.11% |
| 2015 FY | 3.32 Million SEK | -79.24% |
| 2015 Q1 | 2.9 Million SEK | -81.9% |
| 2015 Q4 | 3.32 Million SEK | 103.97% |
| 2015 Q3 | 1.63 Million SEK | -58.07% |
| 2014 Q4 | 16.03 Million SEK | 6.48% |
| 2014 Q1 | - SEK | -100.0% |
| 2014 FY | 16.03 Million SEK | 1768.34% |
| 2014 Q3 | 15.05 Million SEK | 0.0% |
| 2013 Q4 | 858.07 Thousand SEK | 0.0% |
| 2013 FY | 858.07 Thousand SEK | 23.05% |
| 2012 FY | 697.32 Thousand SEK | -19.04% |
| 2011 FY | 861.27 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 48.431% |
| Ziccum AB (publ) | 6.38 Million SEK | -760.52% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -2230.225% |
| BioArctic AB (publ) | 139.5 Million SEK | 60.596% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -58.859% |
| Mendus AB (publ) | 51.22 Million SEK | -7.311% |
| Genovis AB (publ.) | 98.04 Million SEK | 43.935% |
| Intervacc AB (publ) | 21.68 Million SEK | -153.552% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -105.818% |
| Active Biotech AB (publ) | 13.4 Million SEK | -310.224% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 55.662% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -241.068% |
| Aptahem AB (publ) | 8.99 Million SEK | -510.925% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | -34.536% |
| Kancera AB (publ) | 17.97 Million SEK | -205.763% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | -19.034% |
| Fluicell AB (publ) | 8.91 Million SEK | -516.601% |
| Saniona AB (publ) | 86.08 Million SEK | 36.143% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -965.723% |
| Biovica International AB (publ) | 34.76 Million SEK | -58.11% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -371.118% |
| AcouSort AB (publ) | 10.37 Million SEK | -429.678% |
| Xintela AB (publ) | 14.01 Million SEK | -292.223% |
| Abliva AB (publ) | 16.78 Million SEK | -227.573% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 74.385% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -375.149% |
| OncoZenge AB (publ) | 1.69 Million SEK | -3135.433% |
| Amniotics AB (publ) | 10.54 Million SEK | -421.191% |
| 2cureX AB (publ) | 2.93 Million SEK | -1772.913% |
| CombiGene AB (publ) | 4.15 Million SEK | -1222.666% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -1141.979% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 96.489% |
| Camurus AB (publ) | 414.81 Million SEK | 86.748% |
| Corline Biomedical AB | 6.78 Million SEK | -709.692% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 10.41% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -186.84% |
| I-Tech AB | 16.2 Million SEK | -239.216% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 95.365% |
| Cyxone AB (publ) | 4.69 Million SEK | -1071.069% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -312.44% |
| Biosergen AB | 5.08 Million SEK | -981.023% |
| NextCell Pharma AB | 13.68 Million SEK | -301.562% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 23.493% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -299.156% |
| Nanologica AB (publ) | 79.32 Million SEK | 30.705% |
| SynAct Pharma AB | 51.83 Million SEK | -6.05% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -591.534% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -958.144% |
| LIDDS AB (publ) | 3.75 Million SEK | -1363.525% |
| Lipum AB (publ) | 7.53 Million SEK | -629.239% |
| BioInvent International AB (publ) | 90.45 Million SEK | 39.228% |
| Alzinova AB (publ) | 9.33 Million SEK | -489.112% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 69.73% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -2964.103% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -197.232% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -1332.256% |
| Simris Alg AB (publ) | 148.93 Million SEK | 63.092% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 22.706% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 88.6% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -331.34% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -657.163% |